Table 3 Baseline clinical characteristics of the CYPTAM patients according to CYP2C19 genotypes.
From: Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse
CYP2C19 genotypes | |||||||
|---|---|---|---|---|---|---|---|
*1/*1 (N = 375) | *1/*2 (N = 14) | *2/*2 (N = 19) | *1/*17 (N = 164) | *17/*17 (N = 31) | *2/*17 (N = 47) | P value | |
Age at enrolment (years) | |||||||
Mean (SD) | 56.0 (11.0) | 60.3 (9.5) | 55.6 (10.2) | 55.8 (11.6) | 57.0 (9.8) | 59.1 (11.7) | 0.347 |
Tumor stage | |||||||
T1 | 0.840 | ||||||
N | 203 | 10 | 11 | 86 | 13 | 23 | |
% | 58.7% | 2.9% | 3.2% | 24.9% | 3.8% | 6.6% | |
T2 | |||||||
N | 153 | 4 | 8 | 68 | 16 | 20 | |
% | 56.9% | 1.5% | 3.0% | 25.3% | 5.9% | 7.4% | |
T3/T4 | |||||||
N | 14 | 0 | 0 | 9 | 2 | 2 | |
% | 51.9% | 0.0% | 0.0% | 33.3% | 7.4% | 7.4% | |
Not specified | |||||||
N | 5 | 0 | 0 | 2 | 0 | 2 | |
% | 55.6% | 0.0% | 0.0% | 22.2% | 0.0% | 22.2% | |
Nodal stage | |||||||
N0 | 0.037 | ||||||
N | 166 | 11 | 12 | 78 | 16 | 26 | |
% | 53.7% | 3.6% | 3.9% | 25.2% | 5.2% | 8.4% | |
N1 | |||||||
N | 166 | 3 | 6 | 64 | 9 | 12 | |
% | 63.8% | 1.2% | 2.3% | 24.6% | 3.5% | 4.6% | |
N2 | |||||||
N | 34 | 0 | 0 | 16 | 2 | 5 | |
% | 59.6% | 0.0% | 0.0% | 28.1% | 3.5% | 8.8% | |
N3 | |||||||
N | 7 | 0 | 1 | 7 | 4 | 3 | |
% | 31.8% | 0.0% | 4.5% | 31.8% | 18.2% | 13.6% | |
Not specified | |||||||
N | 2 | 0 | 0 | 0 | 0 | 1 | |
% | 66.7% | 0.0% | 0.0% | 0.0% | 0.0% | 33.3% | |
Histological classification | |||||||
Ductal adenocarcinoma | 0.662 | ||||||
N | 280 | 11 | 13 | 131 | 22 | 38 | |
% | 56.6% | 2.2% | 2.6% | 26.5% | 4.4% | 7.7% | |
Lobular adenocarcinoma | |||||||
N | 54 | 3 | 3 | 18 | 7 | 6 | |
% | 59.3% | 3.3% | 3.3% | 19.8% | 7.7% | 6.6% | |
Other | |||||||
N | 39 | 0 | 3 | 16 | 2 | 2 | |
% | 62.9% | 0.0% | 4.8% | 25.8% | 3.2% | 3.2% | |
Not specified | |||||||
N | 2 | 0 | 0 | 0 | 0 | 1 | |
% | 66.7% | 0.0% | 0.0% | 0.0% | 0.0% | 33.3% | |
Histological grade | |||||||
G1 | 0.357 | ||||||
N | 46 | 6 | 3 | 22 | 5 | 8 | |
% | 51.1% | 6.7% | 3.3% | 24.4% | 5.6% | 8.9% | |
G2 | |||||||
N | 213 | 7 | 10 | 95 | 19 | 24 | |
% | 57.9% | 1.9% | 2.7% | 25.8% | 5.2% | 6.5% | |
G3 | |||||||
N | 113 | 1 | 6 | 46 | 6 | 14 | |
% | 60.8% | 0.5% | 3.2% | 24.7% | 3.2% | 7.5% | |
Not specified | |||||||
N | 3 | 0 | 0 | 2 | 1 | 1 | |
% | 42.9% | 0.0% | 0.0% | 28.6% | 14.3% | 14.3% | |
Progesterone receptor status | |||||||
Positive | 0.476 | ||||||
N | 293 | 14 | 14 | 136 | 26 | 35 | |
% | 56.6% | 2.7% | 2.7% | 26.3% | 5.0% | 6.8% | |
Negative | |||||||
N | 77 | 0 | 5 | 26 | 5 | 10 | |
% | 62.6% | 0.0% | 4.1% | 21.1% | 4.1% | 8.1% | |
Not specified | |||||||
N | 5 | 0 | 0 | 3 | 0 | 2 | |
% | 50.0% | 0.0% | 0.0% | 30.0% | 0.0% | 20.0% | |
HER2 receptor status | |||||||
0 | 0.003 | ||||||
N | 232 | 6 | 9 | 103 | 24 | 23 | |
% | 58.4% | 1.5% | 2.3% | 25.9% | 6.0% | 5.8% | |
1 + | |||||||
N | 98 | 4 | 5 | 35 | 6 | 17 | |
% | 59.4% | 2.4% | 3.0% | 21.2% | 3.6% | 10.3% | |
2 + | |||||||
N | 11 | 4 | 3 | 14 | 0 | 2 | |
% | 32.4% | 11.8% | 8.8% | 41.2% | 0.0% | 5.9% | |
3 + | |||||||
N | 32 | 0 | 2 | 13 | 1 | 4 | |
% | 61.5% | 0.0% | 3.8% | 25.0% | 1.9% | 7.7% | |
Not specified | |||||||
N | 2 | 0 | 0 | 0 | 0 | 1 | |
% | 66.7% | 0.0% | 0.0% | 0.0% | 0.0% | 33.3% | |
FISH | |||||||
Positive (amplification) | 0.745 | ||||||
N | 35 | 0 | 2 | 14 | 1 | 4 | |
% | 62.5% | 0.0% | 3.6% | 25.0% | 1.8% | 7.1% | |
Negative | |||||||
N | 338 | 14 | 17 | 151 | 30 | 42 | |
% | 57.1% | 2.4% | 2.9% | 25.5% | 5.1% | 7.1% | |
Not specified | |||||||
N | 2 | 0 | 0 | 0 | 0 | 1 | |
% | 66.7% | 0.0% | 0.0% | 0.0% | 0.0% | 33.3% | |
Surgery | |||||||
Mastectomy | 0.503 | ||||||
N | 168 | 2 | 10 | 82 | 16 | 22 | |
% | 56.0% | 0.7% | 3.3% | 27.3% | 5.3% | 7.3% | |
Breast conserving | |||||||
N | 204 | 12 | 9 | 82 | 15 | 24 | |
% | 59.0% | 3.5% | 2.6% | 23.7% | 4.3% | 6.9% | |
Not specified | |||||||
N | 3 | 0 | 0 | 1 | 0 | 1 | |
% | 60.0% | 0.0% | 0.0% | 20.0% | 0.0% | 20.0% | |
Surgery axilla | |||||||
Sentinal node procedure only | 0.734 | ||||||
N | 183 | 11 | 9 | 84 | 14 | 24 | |
% | 56.3% | 3.4% | 2.8% | 25.8% | 4.3% | 7.4% | |
Axillary lymph node dissection | |||||||
N | 189 | 3 | 10 | 80 | 17 | 22 | |
% | 58.9% | 0.9% | 3.1% | 24.9% | 5.3% | 6.9% | |
Not specified | |||||||
N | 3 | 0 | 0 | 1 | 0 | 1 | |
% | 60.0% | 0.0% | 0.0% | 20.0% | 0.0% | 20.0% | |
Adjuvant radiotherapy | |||||||
Yes | 0.237 | ||||||
N | 260 | 13 | 9 | 111 | 23 | 33 | |
% | 57.9% | 2.9% | 2.0% | 24.7% | 5.1% | 7.3% | |
No | |||||||
N | 113 | 1 | 10 | 54 | 8 | 13 | |
% | 56.8% | 0.5% | 5.0% | 27.1% | 4.0% | 6.5% | |
Not specified | |||||||
N | 2 | 0 | 0 | 0 | 0 | 1 | |
% | 66.7% | 0.0% | 0.0% | 0.0% | 0.0% | 33.3% | |
Adjuvant chemotherapy | |||||||
Yes | 0.058 | ||||||
N | 235 | 2 | 11 | 103 | 19 | 27 | |
% | 59.2% | 0.5% | 2.8% | 25.9% | 4.8% | 6.8% | |
No | |||||||
N | 138 | 12 | 8 | 62 | 12 | 19 | |
% | 55.0% | 4.8% | 3.2% | 24.7% | 4.8% | 7.6% | |
Not specified | |||||||
N | 2 | 0 | 0 | 0 | 0 | 1 | |
% | 66.7% | 0.0% | 0.0% | 0.0% | 0.0% | 33.3% | |
Trastuzumab therapy | |||||||
Yes | 0.466 | ||||||
N | 34 | 0 | 2 | 16 | 1 | 3 | |
% | 60.7% | 0.0% | 3.6% | 28.6% | 1.8% | 5.4% | |
No | |||||||
N | 338 | 14 | 17 | 148 | 30 | 42 | |
% | 57.4% | 2.4% | 2.9% | 25.1% | 5.1% | 7.1% | |
Not specified | |||||||
N | 3 | 0 | 0 | 1 | 0 | 2 | |
% | 50.0% | 0.0% | 0.0% | 16.7% | 0.0% | 33.3% | |
Menopausal status | |||||||
Premenopausal (age ≤ 45 years) | 0.370 | ||||||
N | 49 | 2 | 2 | 31 | 3 | 4 | |
% | 53.8% | 2.2% | 2.2% | 34.1% | 3.3% | 4.4% | |
Postmenopausal (age ≥ 45 years) | |||||||
N | 326 | 12 | 17 | 133 | 28 | 43 | |
% | 58.3% | 2.1% | 3.0% | 23.8% | 5.0% | 7.7% | |
